Guangdi Li

7.9k total citations · 3 hit papers
97 papers, 5.1k citations indexed

About

Guangdi Li is a scholar working on Epidemiology, Infectious Diseases and Molecular Biology. According to data from OpenAlex, Guangdi Li has authored 97 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Epidemiology, 32 papers in Infectious Diseases and 24 papers in Molecular Biology. Recurrent topics in Guangdi Li's work include Hepatitis B Virus Studies (28 papers), Hepatitis C virus research (23 papers) and HIV/AIDS drug development and treatment (18 papers). Guangdi Li is often cited by papers focused on Hepatitis B Virus Studies (28 papers), Hepatitis C virus research (23 papers) and HIV/AIDS drug development and treatment (18 papers). Guangdi Li collaborates with scholars based in China, Belgium and United States. Guangdi Li's co-authors include Erik De Clercq, Richard J. Whitley, Rolf Hilgenfeld, Yali Wang, Anne–Mieke Vandamme, Miao Miao, Kristof Theys, Haizhen Zhu, Supinya Piampongsant and Mengmeng Guo and has published in prestigious journals such as Nature Communications, The Journal of Immunology and PLoS ONE.

In The Last Decade

Guangdi Li

95 papers receiving 5.0k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

2020 1.3k citations Guangdi Li, Erik De Clercq Nature Reviews Drug Discovery profile →
Approved Antiviral Drugs over the Past 50 Years

2016 1.0k citations Erik De Clercq, Guangdi Li profile →
Therapeutic strategies for COVID-19: progress and lessons learned

2023 341 citations Guangdi Li, Rolf Hilgenfeld et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Guangdi Li China	31	2.3k	1.4k	1.2k	650	511	97	5.1k
Joy Y. Feng United States	30	5.2k 2.3×	1.4k 1.0×	822 0.7×	286 0.4×	633 1.2×	67	6.6k
Sui‐Yuan Chang Taiwan	36	2.2k 0.9×	1.9k 1.3×	1.5k 1.3×	505 0.8×	148 0.3×	247	5.7k
Terrie E. Taylor United States	61	1.4k 0.6×	1.2k 0.8×	1.1k 0.9×	3.0k 4.6×	933 1.8×	262	13.3k
Hans Wilhelm Doerr Germany	53	3.7k 1.6×	1.9k 1.3×	3.2k 2.6×	1.4k 2.1×	443 0.9×	263	9.6k
Shailendra K. Saxena India	39	1.4k 0.6×	1.7k 1.2×	826 0.7×	717 1.1×	206 0.4×	253	5.4k
Egor P. Tchesnokov Canada	24	2.4k 1.0×	856 0.6×	557 0.5×	163 0.3×	355 0.7×	41	3.4k
Adrian S. Ray United States	44	4.4k 1.9×	1.6k 1.1×	2.0k 1.7×	180 0.3×	233 0.5×	110	7.3k
Sandra Ciesek Germany	40	3.1k 1.3×	979 0.7×	1.7k 1.4×	679 1.0×	192 0.4×	175	5.8k
Jianguo Wu China	54	3.4k 1.5×	4.4k 3.1×	1.9k 1.6×	2.0k 3.1×	222 0.4×	273	10.7k

Countries citing papers authored by Guangdi Li

Since Specialization

Citations

This map shows the geographic impact of Guangdi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangdi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangdi Li more than expected).

Fields of papers citing papers by Guangdi Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangdi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangdi Li. The network helps show where Guangdi Li may publish in the future.

Co-authorship network of co-authors of Guangdi Li

This figure shows the co-authorship network connecting the top 25 collaborators of Guangdi Li. A scholar is included among the top collaborators of Guangdi Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangdi Li. Guangdi Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Qi, Jingyi Hu, Yue Wang, et al.. (2025). The Effect of HBV Therapy on Glycemic Control in HBV‐Infected Patients With Diabetes: A 90‐day Multicenter Study. Journal of Medical Virology. 97(2). e70185–e70185. 3 indexed citations

Wang, Yue, Jing Cao, Qi Liu, et al.. (2025). Association between respiratory pathogens and severe clinical outcomes in people living with HIV-1 and pulmonary infections: A 180-day longitudinal cohort study. Journal of Infection and Public Health. 18(4). 102694–102694. 2 indexed citations

Huang, Jie, Qixiang Song, Pan Zhang, et al.. (2025). AntiviralDB: an expert-curated database of antiviral agents against human infectious diseases. mBio. 16(10). e0201325–e0201325. 1 indexed citations

Li, Guangdi, Rolf Hilgenfeld, Richard J. Whitley, & Erik De Clercq. (2023). Therapeutic strategies for COVID-19: progress and lessons learned. Nature Reviews Drug Discovery. 22(6). 449–475. 341 indexed citations breakdown →

Cai, Ting, Ming Xu, Pan Zhang, et al.. (2023). Poor glycemic control in type‐2 diabetic patients infected with hepatitis B: A retrospective propensity‐matched study. Journal of Medical Virology. 95(3). e28635–e28635. 5 indexed citations

Guo, Mengmeng, Wenyan Cao, Shengwen Chen, et al.. (2022). TRIM21 Regulates Virus-Induced Cell Pyroptosis through Polyubiquitination of ISG12a. The Journal of Immunology. 209(10). 1987–1998. 12 indexed citations

Li, Xiaozhou, Jian Pan, Huiling Li, et al.. (2022). DsbA-L interacts with VDAC1 in mitochondrion-mediated tubular cell apoptosis and contributes to the progression of acute kidney disease. EBioMedicine. 76. 103859–103859. 26 indexed citations

Miao, Miao, Erik De Clercq, & Guangdi Li. (2022). Towards Efficient and Accurate SARS-CoV-2 Genome Sequence Typing Based on Supervised Learning Approaches. Microorganisms. 10(9). 1785–1785. 7 indexed citations

Zhang, Quanquan, Ting Cai, Ming Xu, et al.. (2022). Trends in the disease burden of HBV and HCV infection in China from 1990-2019. International Journal of Infectious Diseases. 122. 476–485. 40 indexed citations

10.

Chen, Jia, Zhiguo Zhou, Wenjing Pan, et al.. (2022). Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID‐19 survivors. Journal of Medical Virology. 95(1). e28340–e28340. 6 indexed citations

11.

Li, Guangdi & Erik De Clercq. (2021). A medicinal chemist who reshaped the antiviral drug industry: John Charles Martin (1951–2021). Medicinal Research Reviews. 42(2). 647–653. 7 indexed citations

12.

Li, Guangdi, et al.. (2021). Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. Molecules. 26(4). 923–923. 33 indexed citations

13.

Li, Guangdi, Yali Wang, & Erik De Clercq. (2021). Approved HIV reverse transcriptase inhibitors in the past decade. Acta Pharmaceutica Sinica B. 12(4). 1567–1590. 76 indexed citations

14.

Li, Jiang, Guangdi Li, Yali Wang, et al.. (2020). C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma. Oncogene. 39(16). 3354–3366. 11 indexed citations

15.

Miao, Miao, et al.. (2020). <p>Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy</p>. Drug Design Development and Therapy. Volume 14. 2759–2774. 30 indexed citations

16.

Li, Xiaozhou, Jian Pan, Huiling Li, et al.. (2020). DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nature Communications. 11(1). 4467–4467. 84 indexed citations

17.

Li, Qian, Yifan Wang, Weijuan Jia, et al.. (2019). Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clinical Cancer Research. 26(7). 1712–1724. 116 indexed citations

18.

Sijmons, Steven, Kim Thys, Mirabeau Mbong Ngwese, et al.. (2015). High-Throughput Analysis of Human Cytomegalovirus Genome Diversity Highlights the Widespread Occurrence of Gene-Disrupting Mutations and Pervasive Recombination. Journal of Virology. 89(15). 7673–7695. 134 indexed citations

19.

Cuypers, Lize, Guangdi Li, Pieter Libin, et al.. (2015). Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1–6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses. 7(9). 5018–5039. 56 indexed citations

20.

Shen, Yuying, et al.. (2010). Effects of conservation tillage on crop yield and carbon pool management index on top soil within a maize-wheat-soy rotation system in the Loess Plateau.. Acta Pratacultural Science. 19(1). 75–82. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact